The Global Drug sales of Revlimid stood at USD 10,057 Millions in 2022
The indicator recorded a historical growth (CAGR) of2.08% between 2019 to 2022 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Lenalidomide (Revlimid) is a thalidomide analogue and an immunomodulatory imide drug (IMiD). It is formulated as hard gelatin capsules for oral route of administration.
Mechanism of Action
Lenalidomide is a thalidomide analogue with immunomodulatory, antiangiogenic and antineoplastic activities. By activating cereblon (a component of a cullin ring E3 ubiquitin ligase enzyme complex), lenalidomide mediates the ubiquitination and subsequent degradation of the substrate proteins (including Aiolos, Ikaros and CK1 alpha), leading to direct cytotoxic and immunomodulatory effects. It also inhibits TNF-alpha production, stimulates T cells, reduces serum levels of the cytokines namely vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).
Revlimid Overview
Revlimid is marketed for the treatment of several indications in Central Nervous System, Gastrointestinal, Immunology, and Oncology therapy areas.
Revlimid in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM), as maintenance therapy in patients with multiple myeloma following autologous hematopoietic stem cell transplantation ( auto-HSCT), is indicated for the treatment of patients with transfusion-dependent anemia due to low -or intermediate -1- risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities, indicated for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. Revlimid is indicated for the treatment of relapsed or refractory multiple myeloma, in combination with dexamethasone is indicated for the treatment of multiple myeloma patients who are not eligible for stem cell transplant and adult T-cell leukemia-lymphoma. Revlimid in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL), and marginal zone lymphoma (MZL).
Revlimid was first approved in 2005 and is sold globally including the US, the UK, France, Germany, and Japan by several pharma giants including Bristol-Myers Squibb Co, Celgene Corp, and BeiGene Ltd. Revlimid drug sales recorded a low-double digit Year on Year growth in 2021. Revlimid drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer